Selection criteria were: Clinical efficacy (300 points), safety (200), tolerability (120), dosage frequency (80), user-friendly formulation (80), drug interactions (60), precautions (60) and documentation (100). Acquisition cost was not taken into consideration to allow a preselection on ...
(FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. It is also used as therapy...
(T) recovery can be variable after ADT. Recently, an oral gonadotropin releasing-hormone (GnRH) antagonist, relugolix, has demonstrated more rapid T recovery than injectable GnRH agonists such as leuprolide. In this study, we sought to evaluate patient characteristics associated with T recovery in ...
FDA is asking the manufacturers of gonadotropin-releasing hormone agonists to add new safety information to the Warnings and Precautions section of the drugs? labels about an increased risk of diabetes and certain cardiovascular diseases.doi:http://www.chromatographyonline.com/lcgc...